| 2.88 -0.02 (-0.69%) | 03-17 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
I-Mab is a biopharmaceutical company, operating at the clinical stage, dedicated to the discovery, advancement, and commercialization of biologic therapies. Its core mission is to address critical medical needs in both oncology and autoimmune diseases. The company boasts a comprehensive pipeline of drug candidates. Among its most advanced programs, Eftansomatropin alfa, a long-acting human growth hormone, has successfully completed Phase 3 clinical trials for pediatric growth hormone deficiency. Similarly, Lemzoparlimab, a CD47 monoclonal antibody, has concluded its Phase 2 clinical evaluation. Other notable assets include Felzartamab, a CD38 antibody currently undergoing Phase 1b/2a development for membranous nephropathy. Both TJ107 and Efineptakin (a long-acting variant), recombinant human IL-7 therapies, are progressing through Phase 2 for cancer treatment-related lymphopenia and immunotherapy applications. The pipeline further comprises Enoblituzumab, a humanized B7-H3 antibody in Phase 2 for head and neck cancer and other malignancies; Uliledlimab, a CD73 antibody, also in Phase 2 for solid tumors; and TJ210, a monoclonal antibody against human C5aR1, which is in Phase 1 for cancer and autoimmune disorders. I-Mab's portfolio also features Plonmarlimab, a GM-CSF monoclonal antibody intended for inflammation and CRS-related therapies, alongside several specialized oncology agents: TJ-L14B (a PD-L1-based tumor-dependent T-cell engager for solid cancers), TJ-CD4B (a tumor-dependent T-cell engager for gastric and other cancers), TJ-L1IF (a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors), and TJ-C64B (a tumor-dependent T-cell engager for ovarian and other cancers). To bolster its development efforts, I-Mab has forged strategic alliances with leading industry partners, including AbbVie Ireland Unlimited Company, Sinopharm Group Co. Ltd., PT Kalbe Genexine Biologics, and Roche Diagnostics. Established in 2014, the company's headquarters are located in Shanghai, People's Republic of China.
Thu, 30 Oct 2025
EX-99.1 - SEC.gov
Fri, 17 Oct 2025
I-Mab to rebrand as NovaBridge and target Hong Kong dual listing - The Pharma Letter
Thu, 12 Jun 2025
I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo Finance
Thu, 24 Apr 2025
I-MAB American (IMAB) Stock Price, News & Analysis - Stock Titan
Tue, 07 Jan 2025
I-Mab pauses CD73 antibody development in pipeline reshuffle - Clinical Trials Arena
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|